Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

relating to the offering was filed with the SEC on October 6, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX fails to submit an ANX-530 NDA, whether by December 31, 2009 or at all; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the submiss
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015 Roche (SIX: RO, ROG; OTCQX: ... EGFR Mutation Test v2 for Premarket Approval (PMA) ... as a companion diagnostic test for AZD9291, an ... patients with an acquired resistant mutation.  ... have adenocarcinoma with tumor containing an EGFR sensitizing ...
(Date:7/29/2015)... Calif. , July 29, 2015  UBM Canon ... San Diego Marriott Marquis & Marina on September 1-2, ... device industry. A highlight of the Business Development track ... Backing from Different Types of Investors, featuring Renee ... Johnson Development Corporation; Brent Ahrens , Partner, Canaan ...
(Date:7/29/2015)... Calif. and CAMBRIDGE, Mass. ... Inc. (NASDAQ: ISIS ), the leader in ... subsidiary, announced today that The New England ... a Phase 2 clinical study evaluating volanesorsen (formerly ... to severely high triglycerides. This publication follows the ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 3Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 4Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 5Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 6Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 7
... Aug. 24 Physicians at Southern,Health have started a ... a new strategy for defeating hepatitis C viral infection, ... Implicit Bioscience,s drug, oglufanide disodium, which works as ... by intranasal,administration to patients with chronic hepatitis C viral ...
... Fund Continued Rapid Growth and Innovation, AUDUBON, Pa., ... implant manufacturer in the world, today announced,the closing of ... led the round and was joined by AIG SunAmerica ... Securities, LLC acted,as sole placement agent. The Series ...
Cached Medicine Technology:Drug in New Hepatitis C Clinical Trial 2Globus Medical Raises $110 Million in Series E Financing Round 2
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay Today Online ... to fund the state’s large prison system, which has amassed largely enough throughout the ... incarceration. In light of President Obama’s recent reduction of non violent drug offender’s prison ...
(Date:7/30/2015)... ... , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive ... as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades ... around the world. , “Like treatment of any other disease or condition, making the ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... , ... Author Dr. Raul Llanos seeks to empower readers to ... book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” (published ... responsibility for ourselves, we can create better realities.” His book illustrates the possibilities of ...
(Date:7/30/2015)... ... , ... After a three year trial designed to study the efficiency and ... “bionic eye,” researchers have determined the trial to be a success, and are recommending ... affected by complete vision loss as a result of Retinitis pigmentosa. The results of ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... The full color LCD ... familiar joystick controls, enable any ... make quick and accurate measurements.,Measurement ... the color screen, and results ...
... Patients who need punctal ... dry eye relief. They also ... be as comfortable and as ... why Alcon punctal plugs are ...
... to diagnostic images and reports, the powerful ... scaled to meet the needs of virtually ... Web PACS system allows clinicians, referring physicians, ... view images and information on-site or at ...
... SonoAce 9900 is a ... ultrasound system, with an ... DICOM compatible, designed for ... imaging, obstetrics, gynecology, perinatology, ...
Medicine Products: